Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of C-14-labeled R- and S-verapamil in plasma

Research output: Contribution to journalArticle

Published copy (DOI)

Author(s)

Department/unit(s)

Publication details

JournalBIOANALYSIS
DatePublished - Mar 2010
Issue number3
Volume2
Number of pages9
Pages (from-to)397-405
Original languageEnglish

Abstract

Background: A microdose study was performed where 50 mu g R/S-C-14-verapamil was dosed intravenously to human volunteers. In order to quantify the individual R- and S-enantiomers in human plasma a 2D chiral HPLC method with subsequent analysis by accelerator mass spectrometry was verified. Results: R/S-verapamil was separated on a C18 column and the isolated fraction was applied to a chiral column where the verapamil enantiomers were separated. Experimental recovery (similar to 73% [coefficient of variation {CV} = 16%] and 66% [CV = 21%] for R- and S-verapamil, respectively) was accounted for by the use of internal standardization from the fluorescence response of nonlabeled R- and S-verapamil. The precision of the assay ranged from 4.1 to 15.9% CV and the limit of quantitation was 1.95-4.81 pg/ml for R-verapamil and 1.76-3.34 pg/ml for S-verapamil. Conclusion: This method was successfully applied to the analysis of R- and S-verapamil in human plasma.

    Research areas

  • PHARMACOKINETICS, NORVERAPAMIL, FEXOFENADINE, ABSORPTION, AMS

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations